| Bristol-Myers Squibb SA - Lenalidomid BMS 7,5 mg, Hartkapseln | | 68490 | | 03 | | Lenalidomid BMS 7,5 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 14.06.2021 | | |
| | Composition | | lenalidomidum 7.5 mg, lactosum 144.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, Kapselhülle: gelatina, E 171, E 172 (flavum), Drucktinte: lacca, propylenglycolum, E 172 (nigrum), kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Active Agent | Dose |
|---|
| Lenalidomidum | 7.5 mg |
| | BAG: Active Agent | Dose |
|---|
| Lenalidomidum | 7.5 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| (Flavum) | | | | (Nigrum) | | | | Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Kalii Hydroxidum | | | | Lacca | | Drucktinte | | Lactosum | 144.5 mg | | | Magnesii Stearas | | | | Pro Capsula | | | | Propylenglycol | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | 21 | 726.28 | 806.30 | A | SL | Yes |
|
|
